Investment Rating - The industry rating is "Outperform the Market" [8] Core Insights - The top-level policy for traditional Chinese medicine (TCM) has been clarified, emphasizing high-quality development and supporting industry leaders. The "Implementation Plan for High-Quality Development of the Traditional Chinese Medicine Industry (2026-2030)" was released on February 6, 2026, outlining the development framework for the next five years. The plan highlights the importance of leading companies and innovation in driving industry growth [5][16][21]. - The TCM sector is expected to experience a turning point due to policy support, improved consumer environment, declining raw material prices, and inventory clearance. Key companies to watch include brand TCM firms like China Resources Sanjiu, Dong-E E-Jiao, Jiangzhong Pharmaceutical, and Mayinglong, as well as innovative TCM drug companies like Yiling Pharmaceutical and Fangsheng Pharmaceutical [5][22]. Market Review - In the week from February 2 to February 6, 2026, the CITIC Pharmaceutical Index rose by 0.3%, outperforming the CSI 300 Index by 1.7 percentage points, ranking 12th among CITIC's primary industry classifications. Since the beginning of 2026, the CITIC Pharmaceutical and Biotech sector index has increased by 3.3%, also outperforming the CSI 300 Index by 3.0 percentage points, ranking 19th [4][25]. - The top five performing stocks during this week were: Guangshentang (+29.8%), Haixiang Pharmaceutical (+18.6%), Meidixi (+18.0%), Tianzhihang (+17.6%), and Saike Xide (+14.5%) [4][39]. Short-term Investment Thoughts - The pharmaceutical sector has shown signs of recovery after a period of adjustment, with market sentiment expected to reverse around the Spring Festival. The performance of traditional Chinese medicine has been particularly strong, likely due to the recent policy announcements. The report suggests focusing on innovative drugs, medical devices, and companies benefiting from domestic demand [6][22]. - Recommended stocks for February include Heng Rui Medicine, Kangfang Biotech, Baiji Shenzhou, Ying'en Biotech, Tiger Medical, Microelectrophysiology, Huana Pharmaceutical, and Haite Biotech [6][12].

Group 1 - The company is closely monitoring the normalization of centralized procurement in the pharmaceutical industry and the trends in innovative drug development [2] - The company is focusing on its core pharmaceutical business and continuously promoting product innovation and research and development [2] - The company plans to leverage its advantages across the entire pharmaceutical industry chain to strategically manage R&D investments and carefully assess the direction and pace of innovative drug development [2]

2025年，北京市医疗保障局、北京市卫生健康委员会等九部门联合印发《北京市支持创新医药高质量发 展若干措施（2025年）》（以下简称"新32条"），将临床试验审评审批时限大幅压缩，更在市场准入、 医保支付、投融资支持及生产智造升级等环节同步推出务实举措。 Q：贵公司选择在北京发展，主要看中了北京的哪些独特优势？ 北京创新药正蓬勃向前。 来自科学技术界的市政协委员、北京嘉林药业股份有限公司总裁刘伟，在政协北京市第十四届委员会第 四次会议期间接受了北京商报记者采访。刘伟谈到，"新32条"措施，从研、产、审、用全链条加强了对 创新药械的支持，解决了制约行业发展的一系列痛点问题，可以感受到北京对医药创新的支持更系统、 更务实，既为医药制造升级指明了前瞻性方向，也为创新药从研发到成果转化营造了良好的产业环境。 在刘伟看来，创新药是医药健康赛道的"压舱石"，是必须抓住的核心关键。刘伟建议，进一步聚焦创新 药发展各环节，系统性优化支持政策，凝聚协同创新合力，持续推动创新药高质量发展。 Q：北京"新32条"措施中，哪些政策对公司的研发和产业化帮助最大？"新32条"出台以来，您感受到了 哪些变化？获得了哪些实质性的支持和发展便 ...

Core Viewpoint - The importance of health insurance is increasing due to the growing health protection needs of the public and the advancement of the Healthy China strategy [1] Group 1: Industry Growth and Development - The commercial health insurance sector has experienced an average annual compound growth rate of over 20% in the past decade, with more than 11,000 medical insurance products currently available [3] - By 2025, the total compensation amount for innovative drugs and devices from commercial health insurance is estimated to reach approximately 14.7 billion, with a compound annual growth rate of 70% over four consecutive years [3] Group 2: Collaboration and Innovation - The China Insurance Industry Association is actively promoting cross-industry communication and collaboration with health, medical, and academic organizations to enhance the development of commercial insurance [4] - The actuarial association is working on compiling a net cost table for commercial medical insurance to improve the matching of insurance rates with underwriting risks [6] Group 3: Financial Support for Healthcare - Insurance funds are playing a crucial role in supporting the upgrade of the medical and health care industry, with over 150 billion allocated through various investment plans by 2025 [8] - Direct investments in the medical and elderly care sectors by insurance funds reached nearly 30 billion by the end of Q3 2025, covering various sub-sectors such as biotechnology and medical devices [8] Group 4: Infrastructure and Data Sharing - The Silver Insurance Trust Company is enhancing the infrastructure for health insurance by providing diverse services such as product verification, risk control, and claims support [11] - Future efforts will focus on optimizing health insurance product verification, integrating data between health insurance and medical insurance, and upgrading platform infrastructure to support high-quality development in health insurance [12]

Group 1 - The core viewpoint of the article highlights the rapid growth of BD transactions and the continuous catalysis of innovative drugs, emphasizing the investment value of the Hang Seng Biotechnology ETF (520933) [1] - Over the past decade, the Chinese pharmaceutical industry has undergone a transformation driven by policy support, leading to industrial upgrades [1] - The implementation of the "Full Chain Support for Innovative Drug Development" plan in July 2024 marks a new phase in national support for innovative drugs, elevating their development to a strategic level [1] Group 2 - Chinese innovative drugs have gained international recognition for their innovation and value, indicating a trend towards globalization, whether through independent expansion or licensing-out models [1] - The Hang Seng Biotechnology Index focuses on innovative drugs, showcasing three main advantages: gathering leading companies, scarce futures liquidity, and high elasticity & Sharpe ratio [1] - Investors looking to conveniently participate in core leading innovative drug companies can consider the Hang Seng Biotechnology ETF (520933) for a streamlined investment approach [1]

Group 1 - The core viewpoint of the article highlights the rapid growth of BD transactions and the catalytic role of technology, emphasizing the investment value of the Guotai Sci-Tech 200 ETF (589223) [1] - Over the past decade, the Chinese pharmaceutical industry has undergone a transformation driven by policy support, leading to industrial upgrades [1] - The approval of the "Implementation Plan for Supporting the Development of Innovative Drugs" by the State Council in July 2024 marks a new phase in national strategic support for innovative drug development, optimizing various policies to promote breakthroughs [1] Group 2 - China has entered the first tier of global new drug research and development, with the number of self-developed First-in-Class (FIC) drugs increasing from 9 in 2015 to 120 in 2024, representing 31% of the global pipeline, second only to the United States [1] - The international recognition of the innovation and value of Chinese innovative drugs has led to a trend of globalization, with both independent international expansion and licensing-out models experiencing significant growth [1] - The Sci-Tech 200 Index, which aggregates small-cap stocks from the Sci-Tech Board, reflects the development direction of new productive forces, making the Guotai Sci-Tech 200 ETF (589223) an attractive option for investors looking to participate in hard-tech enterprises [2]

Summary of Key Points from the Conference Call Industry Overview - The conference call focuses on the **pharmaceutical and medical device industries** in China, particularly the trends and opportunities for 2025 and beyond [1][2]. Core Insights and Arguments Pharmaceutical Industry - In 2025, the pharmaceutical industry experienced a significant recovery, with the innovation drug sector outperforming the overall market, showing a growth of approximately **60%** compared to the overall industry index increase of less than **10%** [2][3]. - The success of innovative drugs is primarily driven by breakthroughs in international markets, with **8 out of the top 10 global innovative transactions** in 2025 originating from Chinese companies, boosting market confidence [3][4]. - Despite the positive performance of innovative drugs, certain sectors like vaccines and blood disorders still reported negative returns, indicating a strong structural market [2][3]. Medical Devices - The medical device sector shows varied performance across sub-markets, with low-value consumables like nitrile gloves gaining significant market power, while high-value consumables and high-end medical devices are still in the early stages of international expansion [6][7]. - Notable achievements in the medical device sector include significant growth in exports of cardiovascular stents, artificial joints, and pacemakers, with local companies successfully entering developed markets such as the US and EU [7][8]. - High-value consumables differ from pharmaceuticals in that they possess independent intellectual property and innovation, allowing for licensing opportunities. Establishing sales networks in developed countries is expected to mitigate domestic pricing pressures [8][9]. Additional Important Insights - The financing environment for innovative drugs has improved, reversing a downward trend observed in the past two to three years, which is a positive signal for the pharmaceutical industry [10]. - The retail pharmacy sector is undergoing significant changes, with a decline in the number of single-store pharmacies and a recovery in performance for some chain pharmacies due to the closure of unprofitable locations [11]. - The implementation of traceability code policies in 2026 is expected to standardize market competition and accelerate internal consolidation among chain pharmacies [11]. - Future trends in innovation are expected to focus on unmet clinical needs and new technological directions, such as small nucleic acid technology, which has shown promise in traditional treatments [16]. Recommendations for Investment - The pharmaceutical industry is expected to remain promising in 2026, with a focus on innovative directions due to reduced uncertainty compared to previous years [15]. - In the medical device sector, attention should be given to high-value consumables, IVD products, and high-end medical equipment, which are anticipated to have significant growth potential [17]. - Continuous monitoring of CDMO order growth and potential breakthroughs in chain pharmacies and raw materials is recommended, particularly in synthetic biology and contract manufacturing [18].

Market Overview - In December 2025, the A-share market showed a "high-level fluctuation and structural switching" pattern, with the Shanghai Composite Index rising by 2.06% and the Shenzhen Component Index increasing by 4.17%[7] - The average return of the stock portfolio in December was 6.20%, outperforming the CSI 300 Index, which rose by 2.28%[7] Stock Recommendations - **Hengrui Medicine (600276)**: Closing price at 59.57 CNY, focusing on innovative drugs with a projected EPS of 1.31 CNY for 2025[10][12] - **Luoyang Molybdenum (603993)**: Closing price at 20.00 CNY, benefiting from copper and gold business expansion, with an EPS forecast of 0.88 CNY[15][18] - **Huaxin Cement (600801)**: Closing price at 24.54 CNY, with a focus on overseas expansion and an EPS estimate of 1.42 CNY[19][22] - **Sanmei Co., Ltd. (603379)**: Closing price at 60.72 CNY, specializing in refrigerants, with an EPS forecast of 3.50 CNY[23][27] - **CATL (300750)**: Closing price at 367.26 CNY, with a valuation recovery theme and an EPS estimate of 15.00 CNY[28][31] - **Sungrow Power Supply (300274)**: Closing price at 171.04 CNY, benefiting from favorable conditions in new energy storage, with an EPS forecast of 7.12 CNY[32][35] - **Sany Heavy Industry (600031)**: Closing price at 21.13 CNY, focusing on engineering machinery with an EPS estimate of 0.99 CNY[36][39] - **Inovance Technology (300124)**: Closing price at 75.33 CNY, focusing on industrial control with an EPS forecast of 2.07 CNY[40][42] - **North Huachuang (002371)**: Closing price at 459.08 CNY, specializing in semiconductor equipment with an EPS estimate of 9.95 CNY[43][45] Risks and Considerations - The report indicates a medium to high risk level for the stock portfolio, emphasizing the need for cautious investment decisions based on the accuracy and completeness of the information provided[6][3] - Potential risks include macroeconomic fluctuations, raw material price volatility, and regulatory changes affecting industry dynamics[11][18][19]

Core Insights - In 2025, China approved a record 76 innovative drugs, significantly surpassing the 48 approved in 2024, marking a historical high [1] - The total value of innovative drug licensing transactions in China exceeded $130 billion in 2025, with over 150 transactions, also setting a new record [1] Group 1: Drug Approvals - The 76 approved innovative drugs in 2025 include 47 chemical drugs, 23 biological products, and 6 traditional Chinese medicines [1] - Among the 47 chemical drugs, 38 are domestically developed, accounting for 80.85% of the total [1] - For the 23 biological products, 21 are domestic innovations, representing 91.30% of the total [1] Group 2: First-in-Class Drugs - In 2025, 11 first-in-class innovative drugs were approved, with 4 being independently developed in China [1] Group 3: Licensing Transactions - The innovative drug licensing transactions in 2025 exceeded $130 billion, compared to $51.9 billion in 2024, indicating a substantial increase [1] - The number of licensing transactions rose from 94 in 2024 to over 150 in 2025 [1] Group 4: Future Initiatives - Starting in 2026, the National Medical Products Administration (NMPA) plans to implement more measures to accelerate the development of innovative drugs in China [2]

Core Insights - The biopharmaceutical industry in China is experiencing a historic leap in 2025, marked by a record number of innovative drug approvals and a total foreign licensing amount exceeding $100 billion, driven by top-level policy design, industry efforts, and public confidence [1][4][30]. Group 1: Innovative Drugs - As of December 7, 2025, the number of innovative drugs approved for market in China reached 69, a significant increase from 48 in the previous year, indicating a surge in innovative research and development [4]. - The government has emphasized the importance of innovative drugs in healthcare, establishing a pricing mechanism and supporting their development [6][7]. - The approval process for clinical trials of innovative drugs has been expedited, with a new 30-day review system implemented [18][19]. Group 2: Market Transactions - In the first three quarters of 2025, the total amount of foreign licensing transactions in China's pharmaceutical sector reached $920.3 billion, with projections indicating it will surpass $1 trillion by year-end [4][30]. - A notable transaction occurred when 3SBio entered a licensing agreement with Pfizer worth $60.5 billion, highlighting the international recognition of Chinese innovative drugs [12][13]. Group 3: Clinical Advancements - Two new Alzheimer's drugs, Donanemab and Lecanemab, were rapidly approved in China, with the first prescription written in March 2025, showcasing the swift integration of innovative treatments into the market [9][10]. - China's invasive brain-machine interface has entered clinical trials, marking a significant advancement in cutting-edge medical technology [15]. Group 4: Financial Performance - BeiGene reported its first half-year profit in August 2025, indicating a turning point for leading Chinese innovative drug companies as they enter a phase of commercial viability [16][17]. Group 5: Public Health Initiatives - The HPV vaccine was included in the national immunization program, enhancing public health measures and access to preventive care for women [21][22]. - The first version of the commercial health insurance innovative drug directory was released, aiming to improve accessibility to innovative drugs through a dual-channel approach [23][24]. Group 6: Global Positioning - By October 2025, China's total foreign licensing amount for innovative drugs exceeded $100 billion, representing 49% of the global total, surpassing the United States [29][30]. - Despite being the largest supplier of active pharmaceutical ingredients, China's pharmaceutical market remains significantly smaller than that of the U.S., with local companies holding a minimal share of the innovative drug market [28][30]. Group 7: Future Outlook - The combination of policy guidance and industry efforts is expected to accelerate the transition of Chinese innovative drugs from being primarily suppliers of raw materials to becoming influential contributors in the global pharmaceutical landscape [31].